Erratum to: Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Rhee, C. W.; Lee, J.; Oh, S.; Choi, N. K.; Park, B. J.
January 2012
Osteoporosis International;Jan2012, Vol. 23 Issue 1, p255
Academic Journal
Correction Notice
A correction is presented to the article "Use of biphosphonate and risk of atrial fibrillation in older women with osteoporosis," by C. W. Rhee, J. Lee, S. Oh et al. originally published in a previous issue of the journal.


Related Articles

  • Bisphosphonates linked to AF, but not osteonecrosis of the jaw.  // Reactions Weekly;12/3/2011, Issue 1380, p4 

    The article discusses research which showed the association between bisphosphonate use and the risk of atrial fibrillation (AF) flutter among cancer patients but not with the incidence of osteonecrosis of the jaw (ON).

  • Bisphosphonates "modestly" increase risk of AF.  // Reactions Weekly;11/6/2010, Issue 1326, p6 

    The article discusses research on the association of intravenous bisphosphonate use with increased risk of atrial fibrillation (AF) and other cardiovascular events among cancer patients, referencing a study by G. S. Wilkinson, published in the October 12, 2010 issue of the "Journal of Clinical...

  • Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Rhee, C.; Lee, J.; Oh, S.; Choi, N.; Park, B. // Osteoporosis International;Jan2012, Vol. 23 Issue 1, p247 

    Summary: Concerns have been raised among clinicians and patients whether or not bisphosphonates increase the risk of atrial fibrillation. In this large cohort study, increased risk of atrial fibrillation was not found to be associated with bisphosphonate. In fact, bisphosphonate even showed a...

  • Bisphosphonates and increased AF rates: FDA says no clear link.  // Reactions Weekly;11/22/2008, Issue 1229, p3 

    The article announces that the U.S. Food and Drug Administration (FDA) has issued an update to their review of data relating to a potentially increased risk of atrial fibrillation (AF) associated with the use of biphosphonate. It states that the FDA concluded that there was no clear association...

  • Safety review of bisphosphonates.  // WHO Drug Information;2008, Vol. 22 Issue 4, p286 

    The article reports that the U.S. Food and Drug Administration (FDA) is reviweing data on potential side effects of bisphosphonate drugs. Biophosphates are used to increase bone mass and reduce the risk of practure in patients with osteoporosis. It notes that FDA began examining clinical trial...

  • Dabigatran vs warfarin: Less bleeding?  // Internal Medicine Alert;11/17/2009 Supplement, p21 

    The article reports on the results of a study regarding the effective use of dabigatran (DAB) and warfarin (WRF) in the reduction of atrial fibrilation (AF) risk factors.

  • Atrial fibrillation increases risk of stroke mortality.  // Geriatrics;May97, Vol. 52 Issue 5, p100 

    Presents an abstract of the article `Atrial Fibrillation and Stroke: Mortality and Causes of Death After the First Acute Ischemic Stroke,' by MM Kaarisalo, P. Immonen-Raiha, et al from the `Stroke' dated February 1997.

  • QUICK STUDIES. Hearts Aflutter.  // Nutrition Action Health Letter;Sep2010, Vol. 37 Issue 7, p9 

    The article discusses research being done on the prevalence of atrial fibrillation among obese people which references studies published in the 2010 issues of the "Journal of the American College Cardiology" and the "American Journal of Clinical Nutrition."

  • Learn, talk and act to reduce your stroke risk.  // Filipino Post;3/21/2013, p7 

    The article focuses Health Reduce the Risk of Stroke Plan (RRSP) which states that Canadians should invest in the future of their health by learning about atrial fibrillation (AF), knowing about the link of AF and heart stroke and then they should take action to reduce chances of stroke.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics